Panayiotis Panayiotidis

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Andrew H. Wei, Pau Montesinos, Vladimir Ivanov et al. · Blood · 2020 · 725 citations · Full text

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Johan Richter, Joëlle Guilhot, Franz Gruber et al. · The Lancet Oncology · 2018 · 587 citations · Full text

Hematological Malignancy, Medicine, Chronic Myeloid Leukaemia +10

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

Martin Dreyling, Armando Santoro, Luigina Mollica et al. · Journal of Clinical Oncology · 2017 · 386 citations

Immunology, Pathology, Pi3k Inhibitor +17

Interleukin‐2 receptor common γ‐chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: Selective induction of anti‐apoptotic (<i>bcl‐2, bcl‐x_L</i>) but not pro‐apoptotic (<i>bax, bcl‐x_S</i>) gene expression

Arne N. Akbar, Nicola Borthwick, R. Gitendra Wickremasinghe et al. · European Journal of Immunology · 1996 · 356 citations

Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells <i>in vitro</i>

Panayiotis Panayiotidis, Dylan T. Jones, K. Ganeshaguru et al. · British Journal of Haematology · 1996 · 297 citations